Early in-hospital discontinuation of aspirin on the first post-procedural day after percutaneous coronary stent implantation in patients on direct oral anticoagulation.

ABSTRACT:

Background

Previous trials investigating antithrombotic therapy with a direct oral anticoagulant (DOAC) and a P2Y12 inhibitor after percutaneous coronary intervention (PCI), termed dual therapy, allowed a short period of triple therapy including a DOAC, a P2Y12 inhibitor, and aspirin.

Aims

This study aimed to determine whether discontinuation of aspirin on the first post-procedural day is safe or causes ischemic events.

Methods

Ischemic and bleeding events during hospitalization were investigated retrospectively in all patients treated with dual therapy (DOAC + P2Y₁₂ inhibitor, designated as group 1) or triple therapy (DOAC + P2Y₁₂ inhibitor+aspirin, designated as group 2) from day 1 after PCI at our center.

Results

Of 4,564 consecutive PC

SUBMITTER: von Stein P 

PROVIDER: S-EPMC10754416 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature